Effective Combination Immunotherapy through Vessel Normalization Using a Cancer‐Targeting Antiangiogenic Peptide

Effective Combination Immunotherapy through Vessel Normalization Using a Cancer‐Targeting Antiangiogenic Peptide–Antibody Hybrid

Published:2022-02-18 Issue:4 Volume:5 Page:2100151
ISSN:2366-3987
Container-title:Advanced Therapeutics
language:en
Short-container-title:Advanced Therapeutics

Author:

Yu Byeongjun¹²,Yoo Dohyun¹²,Kim Ki Hyun³,Kim Tae Woo¹²,Park Seho¹²,Kim Yujin¹²,Son Youngju¹²,Kim Jinjoo¹²,Noh Ilkoo¹²,Whang Chang‐Hee¹²,Chung Junho³,Jon Sangyong¹²^ORCID

Affiliation:

1. Department of Biological Sciences KAIST Institute for the BioCentury Korea Advanced Institute of Sciences and Technology (KAIST) 291 Daehak‐ro Daejeon 34141 Korea

2. Center for Precision Bio‐Nanomedicine Korea Advanced Institute of Sciences and Technology (KAIST) 291 Daehak‐ro Daejeon 34141 Korea

3. Department of Biochemistry and Molecular Biology Seoul National University College of Medicine 103 Daehak‐ro Seoul 03080 Republic of Korea

Funder

National Research Foundation of Korea

Publisher

Wiley

Subject

Pharmacology (medical),Biochemistry (medical),Genetics (clinical),Pharmaceutical Science,Pharmacology,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/adtp.202100151

Reference30 articles.

1. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

2. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

4. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

5. Cold Tumors: A Therapeutic Challenge for Immunotherapy